Skip to main content Scroll Top

ALZHEIMER Alzheimer's dementia and related syndromes represent a major public health issue with 57 million cases worldwide... Clinical trial Pathophysiology Technology Read more CONCUSSION With more than 6 out of 1000 people affected, concussions are one of the most common injuries in sports (5% of sports injuries*)... Clinical trial Pathophysiology Technology Read more PHOTOBIO- MODULATION Photobiomodulation uses low-intensity light emission from laser or LED sources to regulate biological functions... Biophotonics
Mastering of dosimetry
Transcranial Read more NEWS “I really see the difference”: in just a few sessions of light treatment, under a futuristic helmet, Marie-Alice Yahé, former captain of the French national team... Alzheimer
Concussion
Depression Read more EXECUTIVE SUMMARY REGEnLIFE is a late-stage medical technology company focused on the treatment of neurological conditions. Read more Visuel Alzheimer Slider Commotion cerebrale Slider Photobiomodulation Slider

ALZHEIMER Alzheimer's dementia and related syndromes represent a major public health issue with 57 million cases worldwide... Clinical trial Pathophysiology Technology Read more CONCUSSION With more than 6 out of 1000 people affected, concussions are one of the most common injuries in sports (5% of sports injuries*)... Clinical trial Pathophysiology Technology Read more PHOTOBIO- MODULATION Photobiomodulation uses low-intensity light emission from laser or LED sources to regulate biological functions... Biophotonics
Mastering of dosimetry
Transcranial Read more NEWS “I really see the difference”: in just a few sessions of light treatment, under a futuristic helmet, Marie-Alice Yahé, former captain of the French national team... Alzheimer
Concussion
Depression Read more EXECUTIVE SUMMARY REGEnLIFE is a late-stage medical technology company focused on the treatment of neurological conditions. Read more Alzheimer Slider Commotion cerebrale Slider Visuel Photobiomodulation Slider

ALZHEIMER Alzheimer's dementia and related syndromes represent a major public health issue with 57 million cases worldwide... Clinical trial Pathophysiology Technology Read more CONCUSSION With more than 6 out of 1000 people affected, concussions are one of the most common injuries in sports (5% of sports injuries*)... Clinical trial Pathophysiology Technology Read more PHOTOBIO- MODULATION Photobiomodulation uses low-intensity light emission from laser or LED sources to regulate biological functions... Biophotonics
Mastering of dosimetry
Transcranial Read more NEWS “I really see the difference”: in just a few sessions of light treatment, under a futuristic helmet, Marie-Alice Yahé, former captain of the French national team... Alzheimer
Concussion
Depression Read more EXECUTYVE SUMMARY REGEnLIFE is a late-stage medical technology company focused on the treatment of neurological conditions. Read more Visuel Alzheimer Slider Sport Slider Photobiomodulation Slider
Question VisuelQuestion Visuel
6 out of 1000 people are affected by a concussion each year
Visuel CéphaléesVisuel Céphalées
5% of sports injuries
Internet VisuelInternet Visuel
1.2 million Alzheimer's cases in France and 57 million dementia cases worldwide
RGn: a photomedical neurotechnology developed to treat a broad spectrum of neurological disorders.
Overview

REGEnLIFE is an advanced clinical-stage medical technology company focused on treating neurological conditions. Nearing market launch, it is developing a pioneering, patented therapeutic solution based on biophotonics. This non-invasive and painless application for patients takes the form of a helmet and an abdominal belt to target the brain and/or gut, depending on the pathology. Indeed, recent scientific studies suggest the key role of the brain-gut axis in the development of neurological conditions.

Learn more
View all projects#
R&D
The RGn device developed by REGEnLIFE is currently the only photomedical technology that takes into account emerging hypotheses on the identification of the various pathogenic factors implicated in neurological conditions.
View all projects#
Photobiomodulation

Photobiomodulation uses low-intensity light emission from laser or LED sources to regulate biological functions and achieve therapeutic effects (analgesic, anti-inflammatory, healing)

Neurostimulation Visuel

Neurostimulation, as a non-pharmacological intervention, represents a rapidly expanding field of biomedical research and therapy. It is progressively establishing itself as an alternative or complement to pharmacological treatments for several resistant pathologies.

Alzheimer Visuel

At present, there is no cure for Alzheimer’s disease or way to slow its progression. Medications, treatments and non-medication interventions (NMIs) can help treat symptoms.

Commotion Cérébrale Visuel

6 out of every 1,000 people suffer a concussion every year. [Journal Of Rehabilitation Medicine, 2004] 5% of sports injuries are concussions.

Solutions

REGEnLIFE is able to make its devices available for clinical and preclinical research, and is preparing to market a product dedicated to the treatment of concussions.

Visuel
1
Clinical Research

RGn600: an innovative non-invasive medical device using brain and gut stimulation via photobiomodulation.
REGEnLIFE markets the RGn600 for research purposes, the first medical device targeting the brain and gut to treat neuroinflammation.

Learn more
2
Concussion

REGEnBRAIN: a non-invasive medical device for the treatment of concussions.
REGEnLIFE is preparing to commercialize REGEnBRAIN for acute concussion indication.

Learn more
About Us#
About us

Neurotechnology Research and Development

Innovative medical devices for Alzheimer’s disease and other neurological conditions.
REGEnLIFE is an innovative company based in Montpellier.

Learn more
Team
Professionals, experts, engineers, and researchers united in a multidisciplinary dynamic...
Learn more
Visuel Cérébral
Partnerships
Discover our partners.





Learn more